Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xencor, Inc.
With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.
With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.
In Vivo caught up with Benedikt von Braunmühl at the recent BIO-Europe conference in Munich, Germany, to discuss his first six weeks as CEO at Rentschler Biopharma and the biggest trends impacting contract development and manufacturing organizations (CDMO).
Public Company Edition: CARGO Therapeutics grossed $281.3m, giving it the fifth-largest biopharma IPO this year. Also, Alkermes completed its cancer business spinout as Mural Oncology, which launched with $275m, and Xencor sold Ultomiris and Monjuvi royalties for $215m.
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.